Skip to Content

Iopamidol Pregnancy and Breastfeeding Warnings

Iopamidol is also known as: Iopamidol-370, Isovue-128, Isovue-200, Isovue-250, Isovue-300, Isovue-370, Isovue-M-200, Isovue-M-300

Medically reviewed on April 10, 2018

Iopamidol Pregnancy Warnings

It is not known whether this drug crosses the placental barrier or reaches fetal tissues. However, many injectable contrast agents cross the placental barrier in humans and appear to enter fetal tissues. Intravenously administration does not induce adverse effects on fertility and general reproductive performance in rats. No teratogenic effects attributable to this drug have been observed in teratology studies performed in animals. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. There are no adequate and well controlled studies in pregnant women.

US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

Use is not recommended unless clearly needed.

AU TGA pregnancy category: Not assigned
US FDA pregnancy category: B

Comments: X-ray examination of women should be conducted during the pre-ovulation phase of the menstrual cycle and should be avoided during pregnancy.

See references

Iopamidol Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

Comments: The effects in the nursing infant are unknown.

Animal experiences revealed that this drug is nontoxic in animals after oral administration. Due to the low level of absorption of this drug from the gastrointestinal tract, it is unlikely that a fetus could be exposed to significant levels. Harm to the nursing infant is unlikely to occur.

See references

References for pregnancy information

  1. "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Zhanel GG, Mayer M, Laing N, Adam HJ "Mutant Prevention Concentrations of Levofloxacin Alone and in Combination with Azithromycin, Ceftazidime, Colistin (Polymyxin E), Meropenem, Piperacillin-Tazobactam, and Tobramycin against Pseudomonas aeruginosa." Antimicrob Agents Chemother 50 (2006): 2228-30

References for breastfeeding information

  1. "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide